Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Durbin/Hatch bill

This article was originally published in The Tan Sheet

Executive Summary

HHS Secretary Michael Leavitt has promised to examine legislation mandating adverse event reporting for dietary supplements and OTC drugs, Sen. Richard Durbin (D-Ill.), notes during Jan. 26 confirmation hearing. Durbin and Sen. Orrin Hatch (R-Utah) are working together to create an AER bill with input from industry (1"The Tan Sheet" June 28, 2004, p. 3). "There should be a clearinghouse at FDA for manufacturers to provide data about the safety of their products," Durbin says. "As we develop legislation this year, Leavitt has agreed to review it"...

You may also be interested in...



Senators Durbin, Hatch To Work Together On AER Plan

Dietary supplement industry critic Sen. Richard Durbin (D-Ill.) will work alongside congressional industry supporters to develop legislation to create a mandatory serious adverse event reporting system

Cosmetic And Personal Care Trademark Review: 16 April

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

Health And Wellness Weekly Trademarks Review: 16 April

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097792

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel